Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report - Takeaways - MDSpire

Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report

  • By

  • Maja Machulak

  • Magdalena Zwierzchowska

  • Kinga Łysak

  • Kamil Kośmider

  • Katarzyna Szklener

  • Magdalena Skórzewska

  • May 25, 2026

  • 0 min

Share

  • 1

    Endometrial cancer is a common malignancy in women, particularly during perimenopausal and postmenopausal periods.

  • 2

    A 64-year-old woman with grade I endometrioid adenocarcinoma experienced disease recurrence over three years post-surgery.

  • 3

    Molecular analysis revealed a loss-of-function mutation in the NF1 gene, leading to off-label treatment with everolimus.

  • 4

    Everolimus treatment resulted in complete remission of the patient's cancer, although it caused significant metabolic toxicity.

  • 5

    This case highlights the importance of molecular diagnostics in guiding targeted therapy for recurrent endometrial cancer.

Original Source(s)

Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report

  • by Maja Machulak, Magdalena Zwierzchowska, Kinga Łysak, Kamil Kośmider, Katarzyna Szklener, Magdalena Skórzewska

  • May 25, 2026

Related Content

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma